Table 3.
Comparisons of clinical and laboratory indicators between the two groups of different CT scores.
| Derivation cohort | Validation cohort | |||||
|---|---|---|---|---|---|---|
| Low CT score group (n = 21) | High CT score group (n = 33) | p value | Low CT score group (n = 21) | High CT score group (n = 16) | p value | |
| CT scores | 2 (1–3) | 5 (5–7) | <0.0001 | 2 (1–2) | 5 (4.3–7) | <0.0001 |
| Time of PO50, d | 1 (0–7) | 10 (6.5–19.5) | <0.0001 | 0 (0–13.5) | 20.5 (7.3–27.8) | 0.0068 |
| Length of hospital stay, d | 14 (8.5–20) | 20 (13.5–29) | 0.010 | 25 (17.5–36.5) | 29 (22–40.5) | ns |
| Age, y | 33 (26.5–41) | 34 (26.5–42) | ns | 31.5 ± 8.6 | 32.7 ± 10.1 | ns |
| Female, n(%) | 21 (100) | 31 (93.9) | ns | 20 (95.2) | 15 (96.2) | ns |
| Disease duration, m | 30 (12–57) | 18 (6–42) | ns | 11 (1–87) | 11.5 (2.5–78) | ns |
| Duration of GI symptoms to CT, w | 4 (0.5–14.5) | 1.5 (0.5–3.5) | ns | 5 (3–7.5) | 7.5 (2.3–20.3) | ns |
| SLEDAI score | 7 (4–9) | 8 (6–12.5) | ns | 6 (3.5–16) | 7 (3.25–12.75) | ns |
| Albumin, g/L | 32.1 ± 5.2 | 29.9 ± 6.0 | ns | 30.9 ± 8.0 | 30.3 ± 5.9 | ns |
| Serum amylase, U/L | 79 (67–93.5) | 80 (61–103.5) | ns | 72.5 (51.3–277.8) | 88 (69–120.5) | ns |
| IgG, g/L | 12.9 (10.7–16.1) | 13.4 (10.5–17.2) | ns | 18.3 ± 8.6 | 13.2 ± 4.8 | ns |
| C3, g/L | 0.59 ± 0.23 | 0.42 ± 0.16 | 0.0027 | 0.41 (0.37–0.49) | 0.50 (0.29–0.67) | ns |
| Anti-dsDNA antibody, n(%) | 14 (71.4) | 22 (67.7) | ns | 12 (57.1) | 7 (43.8) | ns |
| Active LN, n(%) | 7 (33.3) | 14 (42.4) | ns | 6 (28.6) | 8 (50.0) | ns |
| NPSLE, n(%) | 0 (0.0) | 2 (6.1) | ns | 3 (14.3) | 1 (6.3) | ns |
| Dosage of GC > 2 mg/kg/d, n(%) | 9 (42.9) | 24 (72.7) | 0.028 | 9 (42.9) | 12 (57.1) | ns |
| TPN, n(%) | 11 (52.4) | 30 (90.1) | 0.0024 | 8 (38.1) | 13 (81.3) | 0.018 |
| TPN ≥ 7d, n(%) | 1 (4.8) | 20 (60.6) | <0.0001 | 5 (23.8) | 10 (62.5) | 0.023 |